PMID- 34478119
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220224
IS  - 2199-1154 (Print)
IS  - 2198-9788 (Electronic)
IS  - 2198-9788 (Linking)
VI  - 9
IP  - 1
DP  - 2022 Mar
TI  - Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of 
      Heart Failure Hospitalization in Patients with Heart Failure with Preserved 
      Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse 
      Urban Population.
PG  - 53-62
LID - 10.1007/s40801-021-00277-0 [doi]
AB  - BACKGROUND: Limited evidence-based therapies exist for the management of heart 
      failure with preserved ejection fraction (HFpEF). Sodium-glucose cotransporter-2 
      inhibitor (SGLT2i) use in patients with systolic heart failure (HFrEF) and 
      type-2-diabetes mellitus (T2DM) is associated with improved cardiovascular (CV) 
      and renal outcomes. OBJECTIVE: We sought to examine whether there is an 
      association of SGLT2i use with improved CV outcomes in patients with HFpEF. 
      PATIENTS AND METHODS: We conducted a single-center, retrospective review of 
      patients with HFpEF and T2DM. The cohort was divided into two groups based on 
      prescription of a SGLT2i or sitagliptin. The primary outcome was heart failure 
      hospitalization (HFH); secondary outcomes were all-cause hospitalization and 
      acute kidney injury (AKI). RESULTS: After propensity score matching, there were 
      250 patients (89 in the SGLT2i group, 161 in the sitagliptin group), with a mean 
      follow-up of 295 days. Univariate Cox regression analysis showed that the SGLT2i 
      group had a reduced risk of HFH versus the sitagliptin group (hazard ratio (HR) 
      0.13; 95% confidence interval (CI) (0.05-0.36); p < 0.001). The SGLT2i group had 
      a decreased risk of all-cause hospitalization (HR 0.48; 95% CI (0.33-0.70); 
      p < 0.001) and SGLT2i had a lower risk of AKI (HR 0.39; 95% CI (0.20-0.74); 
      p = 0.004). CONCLUSIONS: The use of SGLT2is is associated with a reduced 
      incidence of HFH and AKI in patients with HFpEF and T2DM.
CI  - (c) 2021. The Author(s).
FAU - Li, Weijia
AU  - Li W
AD  - Department of Medicine, Jacobi Medical Center/Albert Einstein College of 
      Medicine, The Bronx, NY, USA.
FAU - Katamreddy, Adarsh
AU  - Katamreddy A
AD  - Department of Medicine, Jacobi Medical Center/Albert Einstein College of 
      Medicine, The Bronx, NY, USA.
FAU - Kataria, Rachna
AU  - Kataria R
AD  - Division of Cardiology, Montefiore Medical Center/Albert Einstein College of 
      Medicine, The Bronx, NY, USA.
FAU - Myerson, Merle L
AU  - Myerson ML
AD  - Section of Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center, Geisel 
      School of Medicine, 1 Medical Center Drive, Lebanon, NH, 03756, USA.
FAU - Taub, Cynthia C
AU  - Taub CC
AUID- ORCID: 0000-0002-8594-5067
AD  - Division of Cardiology, Montefiore Medical Center/Albert Einstein College of 
      Medicine, The Bronx, NY, USA. cynthia.c.taub@hitchcock.org.
AD  - Section of Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center, Geisel 
      School of Medicine, 1 Medical Center Drive, Lebanon, NH, 03756, USA. 
      cynthia.c.taub@hitchcock.org.
LA  - eng
PT  - Journal Article
DEP - 20210903
PL  - Switzerland
TA  - Drugs Real World Outcomes
JT  - Drugs - real world outcomes
JID - 101658456
PMC - PMC8844327
COIS- No relevant conflicts of interest to declare.
EDAT- 2021/09/04 06:00
MHDA- 2021/09/04 06:01
PMCR- 2021/09/03
CRDT- 2021/09/03 12:33
PHST- 2021/08/10 00:00 [accepted]
PHST- 2021/09/04 06:00 [pubmed]
PHST- 2021/09/04 06:01 [medline]
PHST- 2021/09/03 12:33 [entrez]
PHST- 2021/09/03 00:00 [pmc-release]
AID - 10.1007/s40801-021-00277-0 [pii]
AID - 277 [pii]
AID - 10.1007/s40801-021-00277-0 [doi]
PST - ppublish
SO  - Drugs Real World Outcomes. 2022 Mar;9(1):53-62. doi: 10.1007/s40801-021-00277-0. 
      Epub 2021 Sep 3.